STAT NewsOriginal article
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
Data ReadoutnegativeNegative
AI Analysis
Summary
Eyepoint's experimental treatment for wet AMD failed to demonstrate maintenance of vision with less frequent injections compared to standard therapy. Despite disappointing results, the company maintains optimism about the program's potential.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Patients failed to maintain vision with less frequent injections compared to standard treatment
Importance:6/10
Sentiment:
-0.60
ophthalmologywet AMDclinical trialinjection frequencyvision treatment
Related Companies
Read the original article
Published by STAT News on August 17, 2026 6:45 PM